Highlights of the fourth quarter and the full year
RTX-240 phase clinical program for advanced solid tumors or recurrent/refractory acute myeloid leukemia (ALE)
It appears that RTX-240 stimulates innate and adaptive immune responses, Rubius Therapeutics believes that all knowledge of the Phase 1 clinical trial will validate its RED PLATFORM® and potentially reduce the threat of clinical progression from its oncology line, specifically for RTX-321. RTX-321 has an encouraging set of preclinical knowledge and expresses combinations of agonists on the moving surface, to the RTX-240. RTX-321 Artificial Antigen Presenting Cell Development Program (aAPC) for Human PapillomaVirus (HPV)16 Positive Cancers
Productions of totally owned production through Rubius
Catalysts and operational targets for 2021
RtX-240RTX-240, Rubius Therapeutics’ main oncology program, is a ready-to-use allogenic mobile treatment candidate product that is designed to provide thousands of copies of the ligand of the 4-1BB (4-1BBL) and IL-15TP (IL-15 transpropriation molecule in IL-15R) in its local forms. The RTX-240 is designed to greatly stimulate the immune formula by activating and generating NK and T mobiles reminiscent to generate a strong anti-tumor response.
In RTX-321RTX-321, the company’s time oncology program, it is an AAPC allogeneic treatment candidate product that is marketed and designed to induce a tumor-specific immune reaction through the emergence of antigen-specific T-mobiles. RTX-321 expresses loads of thousands of copies of a HPV peptide antigen connected to the primary complex’s Class I histocompatibility proteins, the 4-1BBL costimululator molecule, and the CYTOkine IL-12 on the moving surface to mimic human APC-T mobile interactions.
Financial results for the fourth quarter of 2020 Net loss for the fourth quarter of 2020 $40. 5 million or $0. 50 consistent with a non-unusual consistent percentage, compared to $44. 5 million or $0. 56 consistent with a non-unusual consistent percentage in the fourth quarter of 2019.
Overhead and administrative expenses were $14. 1 million in the fourth quarter of 2020, compared to $14. 9 million in the fourth quarter of 2019. Price minimisation is basically due to relief in stock-based repayment expense.
Fiscal year 2020 financial results Net loss for the entire year 2020 $167. 7 million or $2. 08 consistent with a non-unusual consistent percentage, compared to $163. 5 million or $2. 08 consistent with a consistent percentage not unusual for full 2019.
For the whole year 2020, Rubius invested $116. 1 million in R
Overhead and administrative expenses were $50. 3 million in the 12 months of 2020, compared to $57. 2 million at the same time in 2019. Price minimisation is basically due to relief in stock-based depreciation expenses.
About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company introducing a new elegance of drugs called Red Cell Therapeutics ™. The company’s proprietary RED PLATFORM® was designed to genetically engineer and domesticate Red Cell Therapeutics ™, selectively, potently, and commercially available as mobile allogeneic cures for the potential remedy of multiple diseases in multiple healing areas. Rubius’ initial purpose is to advance applicants for RCT ™ products for the remedy of cancer and autoimmune diseases by taking advantage of two distinct healing modalities: a powerful mobile-mobile interaction and tolerance induction. Rubius Therapeutics was recently named one of the best places to work in Massachusetts by the Boston Globe, and its production site was recently named the top five best places to work in Rhode Island among midsize companies through Providence Business News. For more information, visit www. rubiustx. com, stay with us on Twitter or LinkedIn or like us on Facebook. Forward-Looking Statements This press release comprises forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, adding, without limitation, statements relating to our expectations regarding the prospective healing of our product portfolio. red blood mobile cure by adding RTX-240 for treatment of patients with relapsed / refractory or locally complex forged tumors and RTX-321 for treatment of HPV 16 positive cancers, our expectations related to time, recruitment, knowledge additional and the good luck of existing and long-term cohorts and stages of the RTX-240 clinical trial, our expectations related to the biological effects of RTX-240 on innate and adaptive immunity, adding activation and improvement of the number of mobile NK and T mobiles in the RTX-240 clinical trial, and our expectations for the complete Ph ess ai clinic ase 1 body of knowledge and its ability to unleash the RED PLATFORM perspective through our line of mobile red blood cures to remedy cancer, adding our expectations related to the prospect of cure for RTX-321, timelines similar to the phase 1 clinical trial of RTX- 321, our expectations related to our ability to expand our production capabilities, our expectations related to the future useful life of our frozen drug substance for RTX-321, our expectations related to our cash flow and our strategy, business plans and objectives. The words “possibly”, “could”, “could”, “could”, “deserve”, “expect”, “plan”, “anticipate”, “pretend”, “believe”, “estimate” Matrix “Anticipate”, The terms “project”, “prospective”, “continue”, “objective” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements involve those identifying words. All forward-looking statements included in this press release are based on existing control ideals and expectations and are subject to a number of dangers, uncertainties and vital points that could possibly cause occasions or effects to occur. Actuals differ materially from those expressed or implied by any forward-looking statement. the statements involved in this press release, adding, without limitation, the dangers and uncertainties related to our applicants’ progression of healing red blood mobile products and their prospective curing and other known dangers in our SEC filings, adding our Quarterly report on Form 10-Q for the quarter ended September 30, 2020 and upcoming filings with the SEC and hazards and uncertainties similar to the severity and duration of COVID-19 have an effect on our activities and operations. We advise you not to place undue reliance on forward-looking statements, which refer only to the date they are made. We disclaim any legal responsibility to publicly update or revise such statements to reflect any repositioning in expectations or in the occasions, situations or cases on which such statements would possibly be founded, or which would possibly have the probability that actual effects differ from those declared. in forward-looking statements. The forward-looking statements included in this press release constitute our revisions as of the date hereof and should not be construed as constituting your revisions at a later date. We explicitly disclaim any legal responsibility to update any forward-looking statements.
Contacts: Investors Elhan Webb, CFA, Vice President investisseurselhan. [email protected] com Relations
Marissa Hanify Media, Director of Corporate Communications Marissa. [email protected] com
Dan Budwick, 1AB 1 (973) [email protected] com